Fig. 3From: Long-term outcomes and safety of radical transmediastinal esophagectomy with preoperative docetaxel, cisplatin, and 5-fluorouracil combination chemotherapy for locally advanced squamous cell carcinoma of the thoracic esophagusThe overall survival (OS) and relapse-free survival (RFS). The median follow-up of the 16 patients was 35.4 months. The 2-year OS was 93.3% (95% CI, 61.3–99.0), and the 3-year OS was 78.8% (95% CI, 47.3–92.7). The 2-year and 3-year RFS were both 73.3% (95% CI, 43.6–89.1). CI, confidence intervalBack to article page